{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T11:06:09Z","timestamp":1791889569250,"version":"4.3.4"},"reference-count":133,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2008,3,1]],"date-time":"2008-03-01T00:00:00Z","timestamp":1204329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2008,3]]},"DOI":"10.4065\/83.3.355","type":"journal-article","created":{"date-parts":[[2009,1,24]],"date-time":"2009-01-24T01:31:26Z","timestamp":1232760686000},"page":"355-367","source":"Crossref","is-referenced-by-count":404,"title":["Small Cell Lung Cancer"],"prefix":"10.4065","volume":"83","author":[{"given":"Taimur","family":"Sher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace K.","family":"Dy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex A.","family":"Adjei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.4065\/83.3.355_bib1","series-title":"Cancer Facts and Figures 2007","author":"American Cancer Society","year":"2007"},{"issue":"18S suppl","key":"10.4065\/83.3.355_bib2","first-page":"384S","article-title":"Temporal trends in small cell lung cancer: analysis of the national Surveillance, Epidemiology, and End-Results (SEER) database [abstract 7082]","volume":"24","author":"Navada","year":"2006","journal-title":"J Clin Oncol"},{"issue":"28","key":"10.4065\/83.3.355_bib3","doi-asserted-by":"crossref","first-page":"4539","DOI":"10.1200\/JCO.2005.04.4859","article-title":"Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database","volume":"24","author":"Govindan","year":"2006","journal-title":"J Clin Oncol"},{"issue":"suppl 4","key":"10.4065\/83.3.355_bib4","first-page":"A10","article-title":"Changing patterns of lung cancer histology with age and gender","volume":"53","author":"Thompson","year":"1998","journal-title":"Thorax"},{"issue":"12","key":"10.4065\/83.3.355_bib5","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1136\/bmj.317.7173.1614b","article-title":"Women at double risk of small cell lung cancer","volume":"317","author":"Kmietowicz","year":"1998","journal-title":"BMJ"},{"issue":"7","key":"10.4065\/83.3.355_bib6","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1136\/thx.54.7.655b","article-title":"Rising incidence of SCLC in young women [letter]","volume":"54","author":"Cartman","year":"1999","journal-title":"Thorax"},{"issue":"4","key":"10.4065\/83.3.355_bib7","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1093\/ajcp\/102.4.406","article-title":"The spectrum of immunohistochemical staining of small-cell lung carcinoma in specimens from transbronchial and open-lung biopsies","volume":"102","author":"Guinee","year":"1994","journal-title":"Am J Clin Pathol"},{"key":"10.4065\/83.3.355_bib8","series-title":"Robins and Cotran Pathologic Basis of Disease","first-page":"757","year":"2005"},{"issue":"9","key":"10.4065\/83.3.355_bib9","first-page":"97","article-title":"Genetic etiology of lung cancer","volume":"6","author":"Otterson","year":"1992","journal-title":"Oncology (Williston Park)"},{"issue":"4","key":"10.4065\/83.3.355_bib10","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/gcc.2870030407","article-title":"Involvement of the RAF 1 locus, at band 3p25, in the 3p deletion of small-cell lung cancer","volume":"3","author":"Graziano","year":"1991","journal-title":"Genes Chromosomes Cancer"},{"issue":"1","key":"10.4065\/83.3.355_bib11","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/bjc.1993.7","article-title":"Expression of the proto-oncogenes c-met and c-kit and their ligands, hepatocyte growth factor\/scatter factor and stem cell factor, in SCLC cell lines and xenografts","volume":"67","author":"Rygaard","year":"1993","journal-title":"Br J Cancer"},{"issue":"19","key":"10.4065\/83.3.355_bib12","first-page":"6272","article-title":"c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions","volume":"63","author":"Ma","year":"2003","journal-title":"Cancer Res"},{"issue":"2C","key":"10.4065\/83.3.355_bib13","first-page":"1031","article-title":"Haptoglobin \u03b1-subunit and hepatocyte growth factor can potentially serve as serum tumor biomarkers in small cell lung cancer","volume":"24","author":"Bharti","year":"2004","journal-title":"Anticancer Res"},{"issue":"2","key":"10.4065\/83.3.355_bib14","first-page":"620","article-title":"Modulation of the c-Met\/hepatocyte growth factor pathway in small cell lung cancer","volume":"8","author":"Maulik","year":"2002","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.4065\/83.3.355_bib15","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1582-4934.2002.tb00453.x","article-title":"Activated c-Met signals through PI3K with dramatic effects on cytoskeletal functions in small cell lung cancer","volume":"6","author":"Maulik","year":"2002","journal-title":"J Cell Mol Med"},{"issue":"3","key":"10.4065\/83.3.355_bib16","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/sj.bjc.6603884","article-title":"Downstream signalling and specific inhibition of c-MET\/HGF pathway in small cell lung cancer: implications for tumour invasion","volume":"97","author":"Ma","year":"2007","journal-title":"Br J Cancer"},{"issue":"11","key":"10.4065\/83.3.355_bib17","first-page":"3089","article-title":"Expression of the epidermal growth factor receptor in human small cell lung cancer cell lines","volume":"52","author":"Damstrup","year":"1992","journal-title":"Cancer Res"},{"issue":"5","key":"10.4065\/83.3.355_bib18","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/bjc.1998.553","article-title":"In vitro invasion of small-cell lung cancer cell lines correlates with expression of epidermal growth factor receptor","volume":"78","author":"Damstrup","year":"1998","journal-title":"Br J Cancer"},{"issue":"20","key":"10.4065\/83.3.355_bib19","doi-asserted-by":"crossref","first-page":"7159","DOI":"10.1073\/pnas.84.20.7159","article-title":"Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells","volume":"84","author":"Hudziak","year":"1987","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"10.4065\/83.3.355_bib20","first-page":"1859","article-title":"Transformation mediated by the human HER-2 gene independent of the epidermal growth factor receptor","volume":"7","author":"Chazin","year":"1992","journal-title":"Oncogene"},{"issue":"4","key":"10.4065\/83.3.355_bib21","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1002\/ijc.1229","article-title":"c-erbB2 expression in small-cell lung cancer is associated with poor prognosis","volume":"92","author":"Micke","year":"2001","journal-title":"Int J Cancer"},{"issue":"1","key":"10.4065\/83.3.355_bib22","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/01243894-200601000-00004","article-title":"The Ras\/Raf\/MAPK Pathway","volume":"1","author":"Molina","year":"2006","journal-title":"J Thorac Oncol"},{"issue":"2","key":"10.4065\/83.3.355_bib23","first-page":"503","article-title":"High prevalence of bcl-2 oncoprotein expression in small cell lung cancer","volume":"15","author":"Higashiyama","year":"1995","journal-title":"Anticancer Res"},{"issue":"2","key":"10.4065\/83.3.355_bib24","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/path.1711770206","article-title":"Expression of bcl-2 oncogene protein is prevalent in small cell lung carcinomas","volume":"177","author":"Jiang","year":"1995","journal-title":"J Pathol"},{"issue":"2","key":"10.4065\/83.3.355_bib25","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1089\/ard.1994.4.71","article-title":"Reversal of chemoresistance of lymphoma cells by antisense-mediated reduction of bcl-2 gene expression","volume":"4","author":"Kitada","year":"1994","journal-title":"Antisense Res Dev"},{"issue":"9","key":"10.4065\/83.3.355_bib26","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1038\/79542","article-title":"Genetic analysis of chemoresistance in primary murine lymphomas","volume":"6","author":"Schmitt","year":"2000","journal-title":"Nat Med"},{"issue":"2 suppl 4","key":"10.4065\/83.3.355_bib27","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1053\/sonc.2001.25738","article-title":"Molecular genetics of small cell lung carcinoma","volume":"28","author":"Wistuba","year":"2001","journal-title":"Semin Oncol"},{"issue":"19","key":"10.4065\/83.3.355_bib28","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1038\/sj.onc.1203593","article-title":"An N-terminal p14ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo","volume":"19","author":"Midgley","year":"2000","journal-title":"Oncogene"},{"issue":"9","key":"10.4065\/83.3.355_bib29","first-page":"2287","article-title":"Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene","volume":"54","author":"Fujiwara","year":"1994","journal-title":"Cancer Res"},{"issue":"1","key":"10.4065\/83.3.355_bib30","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s10555-006-7887-8","article-title":"Modifying the soil to affect the seed: role of stromal-derived matrix metalloproteinases in cancer progression","volume":"25","author":"Jodele","year":"2006","journal-title":"Cancer Metastasis Rev"},{"issue":"11","key":"10.4065\/83.3.355_bib31","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1002\/cncr.22315","article-title":"Nuclear factor-\u03baB (NF-\u03baB) is frequently expressed in lung cancer and preneoplastic lesions","volume":"107","author":"Tang","year":"2006","journal-title":"Cancer"},{"issue":"1","key":"10.4065\/83.3.355_bib32","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1164\/rccm.200502-235PP","article-title":"Familial lung cancer: genetic susceptibility and relationship to chronic obstructive pulmonary disease","volume":"173","author":"Schwartz","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.4065\/83.3.355_bib33","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1093\/aje\/kwm090","article-title":"Passive smoking, metabolic gene polymorphisms, and infant birth weight in a prospective cohort study of Chinese women","volume":"166","author":"Wu","year":"2007","journal-title":"Am J Epidemiol"},{"issue":"3","key":"10.4065\/83.3.355_bib34","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1086\/423857","article-title":"A major lung cancer susceptibility locus maps to chromosome 6q23-25","volume":"75","author":"Bailey-Wilson","year":"2004","journal-title":"Am J Hum Genet"},{"issue":"10","key":"10.4065\/83.3.355_bib35","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1097\/00008571-200310000-00004","article-title":"The CYP3A4*1B allele increases risk for small cell lung cancer: effect of gender and smoking dose","volume":"13","author":"Dally","year":"2003","journal-title":"Pharmacogenetics"},{"issue":"5","key":"10.4065\/83.3.355_bib36","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1002\/ijc.10756","article-title":"Myeloperoxidase (MPO) genotype and lung cancer histologic types: the MPO -463 A allele is associated with reduced risk for small cell lung cancer in smokers","volume":"102","author":"Dally","year":"2002","journal-title":"Int J Cancer"},{"issue":"3","key":"10.4065\/83.3.355_bib37","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/S0025-6196(12)60050-0","article-title":"Paraneoplastic syndromes associated with lung cancer","volume":"68","author":"Patel","year":"1993","journal-title":"Mayo Clin Proc"},{"issue":"5","key":"10.4065\/83.3.355_bib38","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1378\/chest.82.5.602","article-title":"Pancoast's syndrome and small cell lung cancer","volume":"82","author":"Johnson","year":"1982","journal-title":"Chest"},{"issue":"3","key":"10.4065\/83.3.355_bib39","first-page":"272","article-title":"Clinical biology of small cell carcinoma: relationship to surgical therapy","volume":"5","author":"Mountain","year":"1978","journal-title":"Semin Oncol"},{"key":"10.4065\/83.3.355_bib40","series-title":"Lung Cancer: Principles and Practice","first-page":"78","year":"2005"},{"issue":"1","key":"10.4065\/83.3.355_bib41","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/(SICI)1097-4598(199901)22:1<119::AID-MUS19>3.0.CO;2-5","article-title":"P\/Q-type voltage-gated calcium channel antibodies in paraneoplastic disorders of the central nervous system","volume":"22","author":"Voltz","year":"1999","journal-title":"Muscle Nerve"},{"issue":"6","key":"10.4065\/83.3.355_bib42","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1212\/WNL.50.6.1919","article-title":"Absence of HuD gene mutations in the paraneoplastic small cell lung cancer tissue","volume":"50","author":"Carpentier","year":"1998","journal-title":"Neurology"},{"issue":"6","key":"10.4065\/83.3.355_bib43","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1001\/archinte.1987.00370060066013","article-title":"Lactate dehydrogenase values and bone scans as predictors of bone marrow involvement in small cell lung cancer","volume":"147","author":"Hamrick","year":"1987","journal-title":"Arch Intern Med"},{"issue":"11","key":"10.4065\/83.3.355_bib44","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1002\/1097-0142(19861201)58:11<2538::AID-CNCR2820581129>3.0.CO;2-W","article-title":"Detection of bone marrow relapse in patients with small cell carcinoma of the lung","volume":"58","author":"Kristjansen","year":"1986","journal-title":"Cancer"},{"issue":"3","key":"10.4065\/83.3.355_bib45","doi-asserted-by":"crossref","first-page":"198","DOI":"10.3109\/00313029109063566","article-title":"Hematological, biochemical and bone scan findings in patients with marrow carcinoma","volume":"23","author":"Campbell","year":"1991","journal-title":"Pathology"},{"issue":"5","key":"10.4065\/83.3.355_bib46","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/0360-3016(86)90035-0","article-title":"Prognostic influence of TNM staging and the LDH levels in small cell carcinoma of the lung (SCCL)","volume":"12","author":"Byhardt","year":"1986","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.4065\/83.3.355_bib47","first-page":"278","article-title":"Therapy of small cell lung cancer: a perspective on two decades of clinical research","volume":"15","author":"Seifter","year":"1988","journal-title":"Semin Oncol"},{"issue":"9","key":"10.4065\/83.3.355_bib48","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1200\/JCO.1986.4.9.1307","article-title":"Long-term disease-free survival in small-cell carcinoma of the lung: a study of clinical determinants","volume":"4","author":"Osterlind","year":"1986","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.4065\/83.3.355_bib49","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/1097-0142(20000801)89:3<523::AID-CNCR7>3.0.CO;2-6","article-title":"Prognostic factors for patients with small cell lung carcinoma: analysis of a series of 763 patients included in 4 consecutive prospective trials with a minimum follow-up of 5 years","volume":"89","author":"Paesmans","year":"2000","journal-title":"Cancer"},{"issue":"2","key":"10.4065\/83.3.355_bib50","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3816\/CLC.2002.n.018","article-title":"Small-cell lung cancer: state of the art","volume":"4","author":"Hanna","year":"2002","journal-title":"Clin Lung Cancer"},{"issue":"6","key":"10.4065\/83.3.355_bib51","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1200\/JCO.1992.10.6.890","article-title":"Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? a meta-analysis","volume":"10","author":"Warde","year":"1992","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.4065\/83.3.355_bib52","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1056\/NEJM199212033272302","article-title":"A meta-analysis of thoracic radiotherapy for small-cell lung cancer","volume":"327","author":"Pignon","year":"1992","journal-title":"N Engl J Med"},{"issue":"6 suppl","key":"10.4065\/83.3.355_bib53","doi-asserted-by":"crossref","first-page":"320S","DOI":"10.1378\/chest.106.6.320S","article-title":"A prospective randomized trial to determine the benefit of surgical resection of residual disease following response of small cell lung cancer to combination chemotherapy","volume":"106","author":"Lad","year":"1994","journal-title":"Chest"},{"issue":"2","key":"10.4065\/83.3.355_bib54","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1378\/chest.92.2.241","article-title":"Postchemotherapy resection of residual tumor in limited stage small cell lung cancer","volume":"92","author":"Johnson","year":"1987","journal-title":"Chest"},{"issue":"3","key":"10.4065\/83.3.355_bib55","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0022-5223(19)36720-0","article-title":"Surgical treatment for limited small-cell lung cancer: the University of Toronto Lung Oncology Group experience","volume":"101","author":"Shepherd","year":"1991","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"2","key":"10.4065\/83.3.355_bib56","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S0022-5223(19)36752-2","article-title":"Is there ever a role for salvage operations in limited small-cell lung cancer?","volume":"101","author":"Shepherd","year":"1991","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"4","key":"10.4065\/83.3.355_bib57","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/bjc.1989.117","article-title":"Duration of chemotherapy in small cell lung cancer: a Cancer Research Campaign trial","volume":"59","author":"Spiro","year":"1989","journal-title":"Br J Cancer"},{"issue":"11","key":"10.4065\/83.3.355_bib58","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1200\/JCO.1985.3.11.1471","article-title":"VP-16 and cisplatin as first-line therapy for small-cell lung cancer","volume":"3","author":"Evans","year":"1985","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.4065\/83.3.355_bib59","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1200\/JCO.1988.6.3.451","article-title":"Cisplatin plus etoposide consolidation following cyclophosphamide, doxorubicin, and vincristine in limited stage small-cell lung cancer","volume":"6","author":"Einhorn","year":"1988","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.4065\/83.3.355_bib60","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1200\/JCO.1999.17.1.409","article-title":"Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin","volume":"17","author":"Go","year":"1999","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.4065\/83.3.355_bib61","doi-asserted-by":"crossref","first-page":"4665","DOI":"10.1200\/JCO.2002.12.111","article-title":"Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up","volume":"20","author":"Sundstrom","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.4065\/83.3.355_bib62","series-title":"Carboplatin (JM-8): Current Perspectives and Future Directions","first-page":"283","article-title":"Alternating chemotherapy with doxorubicin, ifosfamide, and vincristine plus cisplatin and etoposide versus doxorubicin, ifosfamide, and vincristine plus carboplatin and etoposide in small cell lung cancer","author":"Wolf","year":"1990"},{"issue":"2","key":"10.4065\/83.3.355_bib63","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1200\/JCO.1998.16.2.642","article-title":"Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small-cell lung cancer: a prospective randomized study of 300 patients","volume":"16","author":"Steward","year":"1998","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.4065\/83.3.355_bib64","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1634\/theoncologist.12-1-79","article-title":"Increasing chemotherapy in small-cell lung cancer: from dose intensity and density to megadoses","volume":"12","author":"Crivellari","year":"2007","journal-title":"Oncologist"},{"issue":"3","key":"10.4065\/83.3.355_bib65","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1200\/JCO.1991.9.3.499","article-title":"Dose-intensity meta-analysis of chemotherapy regimens in small-cell carcinoma of the lung","volume":"9","author":"Klasa","year":"1991","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.4065\/83.3.355_bib66","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1056\/NEJM199312163292504","article-title":"Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer","volume":"329","author":"Arriagada","year":"1993","journal-title":"N Engl J Med"},{"issue":"10","key":"10.4065\/83.3.355_bib67","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1200\/JCO.1994.12.10.2022","article-title":"Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer","volume":"12","author":"Ihde","year":"1994","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.4065\/83.3.355_bib68","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1200\/JCO.1987.5.12.1864","article-title":"Late intensification chemotherapy with autologous bone marrow transplantation in selected small-cell carcinoma of the lung: a randomized study","volume":"5","author":"Humblet","year":"1987","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.4065\/83.3.355_bib69","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1023\/A:1026453922931","article-title":"Standard- and high-dose etoposide, ifosfamide, carboplatin, and epirubicin in 100 patients with small-call lung cancer: a mature follow-up report","volume":"10","author":"Fetscher","year":"1999","journal-title":"Ann Oncol"},{"issue":"3","key":"10.4065\/83.3.355_bib70","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/S0360-3016(03)00715-6","article-title":"Radiation dose escalation in limited-stage small-cell lung cancer","volume":"57","author":"Roof","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.4065\/83.3.355_bib71","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/0360-3016(89)90444-6","article-title":"Importance of radiation dose in achieving improved loco-regional tumor control in limited-stage small-cell carcinoma: an update","volume":"17","author":"Choi","year":"1989","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.4065\/83.3.355_bib72","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0360-3016(02)04493-0","article-title":"Routine use of approximately 60 Gy once-daily thoracic irradiation for patients with limited-stage small-cell lung cancer","volume":"56","author":"Miller","year":"2003","journal-title":"Int J Radiation Oncol Biol Phys"},{"issue":"8","key":"10.4065\/83.3.355_bib73","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.1200\/JCO.1997.15.8.2840","article-title":"Randomized trial of alternating versus sequential radiotherapy\/chemotherapy in limited-disease patients with small-cell lung cancer: a European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group Study","volume":"15","author":"Gregor","year":"1997","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.4065\/83.3.355_bib74","doi-asserted-by":"crossref","first-page":"3054","DOI":"10.1200\/JCO.2002.12.071","article-title":"Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104","volume":"20","author":"Takada","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.4065\/83.3.355_bib75","author":"Okawara"},{"issue":"23","key":"10.4065\/83.3.355_bib76","doi-asserted-by":"crossref","first-page":"4837","DOI":"10.1200\/JCO.2004.01.178","article-title":"Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer [published correction appears in J Clin Oncol. 2005;23(1):248]","volume":"22","author":"Fried","year":"2004","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.4065\/83.3.355_bib77","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1056\/NEJM199901283400403","article-title":"Twice-daily compared with once daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide","volume":"340","author":"Turrisi","year":"1999","journal-title":"N Engl J Med"},{"issue":"9","key":"10.4065\/83.3.355_bib78","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1200\/JCO.1999.17.9.2681","article-title":"Phase III comparison of twice-daily split-course irradiation versus once-daily irradiation for patients with limited stage small-cell lung carcinoma","volume":"17","author":"Bonner","year":"1999","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.4065\/83.3.355_bib79","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1200\/JCO.1999.17.6.1794","article-title":"Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress","volume":"17","author":"Chute","year":"1999","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.4065\/83.3.355_bib80","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1054\/bjoc.2000.1164","article-title":"Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent","volume":"83","author":"Pujol","year":"2000","journal-title":"Br J Cancer"},{"issue":"7","key":"10.4065\/83.3.355_bib81","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1093\/oxfordjournals.annonc.a058931","article-title":"Randomized comparison of etoposide-cisplatinum vs. etoposide-carboplatin and irradiation in small-cell lung cancer: a Hellenic Co-operative Oncology Group study","volume":"5","author":"Skarlos","year":"1994","journal-title":"Ann Oncol"},{"issue":"2","key":"10.4065\/83.3.355_bib82","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1056\/NEJMoa003034","article-title":"Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer","volume":"346","author":"Noda","year":"2002","journal-title":"N Engl J Med"},{"issue":"16S suppl","key":"10.4065\/83.3.355_bib83","article-title":"Randomized, phase III trial comparing irinotecan\/cisplatin (IP) with etoposide\/cisplatin (EP) in patients (pts) with previously untreated, extensive-stage (ES) small cell lung cancer (SCLC) [abstract LBA7004]","volume":"23","author":"Hanna","year":"2005","journal-title":"J Clin Oncol"},{"issue":"18S suppl","key":"10.4065\/83.3.355_bib84","article-title":"Cisplatin (Cis)\/etoposide (VP16) compared to cis\/irinotecan (CPT11) in extensive-stage small cell lung cancer (E-SCLC): Pharmacogenomic (PG) and comparative toxicity analysis of JCOG 9511 and SWOG 0124 [abstract 7524]","volume":"25","author":"Lara","year":"2007","journal-title":"J Clin Oncol"},{"issue":"18S suppl","key":"10.4065\/83.3.355_bib85","article-title":"Randomized phase III trial of irinotecan plus carboplatin versus etoposide plus carboplatin in patients with small cell lung cancer, extensive disease (SCLC-ED): IRIS-Study [abstract 7523]","volume":"25","author":"Hermes","year":"2007","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.4065\/83.3.355_bib86","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/0277-5379(87)90128-3","article-title":"Retreatment with the induction regimen in small cell lung cancer relapsing after an initial response to short term chemotherapy","volume":"23","author":"Postmus","year":"1987","journal-title":"Eur J Cancer Clin Oncol"},{"issue":"2","key":"10.4065\/83.3.355_bib87","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1200\/JCO.1999.17.2.658","article-title":"Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer","volume":"17","author":"von Pawel","year":"1999","journal-title":"J Clin Oncol"},{"issue":"18S suppl","key":"10.4065\/83.3.355_bib88","article-title":"Pemetrexed (P) in relapsed small cell lung cancer (SCLC): preliminary results of a phase II trial [abstract 7716]","volume":"25","author":"Raju","year":"2007","journal-title":"J Clin Oncol"},{"issue":"30","key":"10.4065\/83.3.355_bib89","doi-asserted-by":"crossref","first-page":"4840","DOI":"10.1200\/JCO.2006.07.7016","article-title":"Randomized phase II trial of pemetrexed combined with either cisplatin or carboplatin in untreated extensive-stage small-cell lung cancer [published correction appears in J Clin Oncol. 2007;25(1):167]","volume":"24","author":"Socinski","year":"2006","journal-title":"J Clin Oncol"},{"issue":"suppl 3","key":"10.4065\/83.3.355_bib90","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1016\/S0169-5002(10)80016-9","article-title":"Prophylactic cranial irradiation in small cell lung cancer\u2014an update","volume":"12","author":"Kristjansen","year":"1995","journal-title":"Lung Cancer"},{"issue":"4","key":"10.4065\/83.3.355_bib91","first-page":"338","article-title":"Prophylactic cranial irradiation in small-cell lung cancer","volume":"20","author":"Harris","year":"1993","journal-title":"Semin Oncol"},{"issue":"3","key":"10.4065\/83.3.355_bib92","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1093\/jnci\/87.3.183","article-title":"Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission","volume":"87","author":"Arriagada","year":"1995","journal-title":"J Natl Cancer Inst"},{"issue":"7","key":"10.4065\/83.3.355_bib93","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1056\/NEJM199908123410703","article-title":"Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission","volume":"341","author":"Auperin","year":"1999","journal-title":"N Engl J Med"},{"issue":"5","key":"10.4065\/83.3.355_bib94","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S0025-6196(11)65123-9","article-title":"Cerebral toxicity in patients treated for small cell carcinoma of the lung","volume":"74","author":"Fonseca","year":"1999","journal-title":"Mayo Clin Proc"},{"issue":"7","key":"10.4065\/83.3.355_bib95","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1056\/NEJMoa071780","article-title":"Prophylactic cranial irradiation in extensive small-cell lung cancer","volume":"357","author":"Slotman","year":"2007","journal-title":"N Engl J Med"},{"issue":"18S suppl","key":"10.4065\/83.3.355_bib96","volume":"25","author":"Bentzion","year":"2007","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.4065\/83.3.355_bib97","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1023\/A:1005862730941","article-title":"Cardiotoxicity of a new anthracycline derivative (SM-5887) following intravenous administration to rabbits: comparative study with doxorubicin","volume":"15","author":"Suzuki","year":"1997","journal-title":"Invest New Drugs"},{"issue":"1","key":"10.4065\/83.3.355_bib98","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1349-7006.1989.tb02247.x","article-title":"Antitumor activities of a novel 9-aminoanthracycline (SM-5887) against mouse experimental tumors and human tumor xenografts","volume":"80","author":"Morisada","year":"1989","journal-title":"Jpn J Cancer Res"},{"issue":"1","key":"10.4065\/83.3.355_bib99","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1349-7006.1989.tb02248.x","article-title":"Toxicological aspects of a novel 9-aminoanthracycline, SM-5887","volume":"80","author":"Morisada","year":"1989","journal-title":"Jpn J Cancer Res"},{"issue":"2","key":"10.4065\/83.3.355_bib100","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1023\/A:1006088907271","article-title":"Chronic effects of a novel synthetic anthracycline derivative (SM-5887) on normal heart and doxorubicin-induced cardiomyopathy in beagle dogs","volume":"16","author":"Noda","year":"1998","journal-title":"Invest New Drugs"},{"issue":"34","key":"10.4065\/83.3.355_bib101","doi-asserted-by":"crossref","first-page":"5448","DOI":"10.1200\/JCO.2006.08.4145","article-title":"Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301","volume":"24","author":"Onoda","year":"2006","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.4065\/83.3.355_bib102","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMc053610","article-title":"EGFR mutations in small-cell lung cancers in patients who have never smoked [letter]","volume":"355","author":"Zakowski","year":"2006","journal-title":"N Engl J Med"},{"issue":"6","key":"10.4065\/83.3.355_bib103","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1093\/annonc\/mdj114","article-title":"EGFR mutation in gefitinib-responsive small-cell lung cancer [letter]","volume":"17","author":"Okamoto","year":"2006","journal-title":"Ann Oncol"},{"issue":"11","key":"10.4065\/83.3.355_bib104","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1111\/j.1349-7006.2007.00600.x","article-title":"Epidermal growth factor receptor mutation status and clinicopathological features of combined small cell carcinoma with adenocarcinoma of the lung","volume":"98","author":"Fukui","year":"2007","journal-title":"Cancer Sci"},{"issue":"3","key":"10.4065\/83.3.355_bib105","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.lungcan.2007.05.014","article-title":"Sequential occurrence of non-small cell and small cell lung cancer with the same EGFR mutation","volume":"58","author":"Morinaga","year":"2007","journal-title":"Lung Cancer"},{"issue":"12, pt 2","key":"10.4065\/83.3.355_bib106","doi-asserted-by":"crossref","first-page":"4254s","DOI":"10.1158\/1078-0432.CCR-040016","article-title":"Farnesyl transferase inhibitors for patients with lung cancer","volume":"10","author":"Johnson","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.4065\/83.3.355_bib107","first-page":"1353","article-title":"Mutations of ras genes distinguish a subset of non-small-cell lung cancer cell lines from small-cell lung cancer cell lines","volume":"6","author":"Mitsudomi","year":"1991","journal-title":"Oncogene"},{"issue":"22","key":"10.4065\/83.3.355_bib108","first-page":"5302","article-title":"A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines","volume":"55","author":"Sepp-Lorenzino","year":"1995","journal-title":"Cancer Res"},{"issue":"8","key":"10.4065\/83.3.355_bib109","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1093\/annonc\/mdh315","article-title":"Phase II study of the farnesyl transferase inhibitor R115777 in patients with sensitive relapse small-cell lung cancer","volume":"15","author":"Heymach","year":"2004","journal-title":"Ann Oncol"},{"issue":"8","key":"10.4065\/83.3.355_bib110","first-page":"3319","article-title":"The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth","volume":"6","author":"Krystal","year":"2000","journal-title":"Clin Cancer Res"},{"issue":"16, pt 1","key":"10.4065\/83.3.355_bib111","first-page":"5880","article-title":"Phase II study of imatinib in patients with small cell lung cancer","volume":"9","author":"Johnson","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.4065\/83.3.355_bib112","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1093\/annonc\/mdi365","article-title":"A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study","volume":"16","author":"Dy","year":"2005","journal-title":"Ann Oncol"},{"issue":"9","key":"10.4065\/83.3.355_bib113","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1097\/JTO.0b013e31814617b7","article-title":"Irinotecan, carboplatin, and imatinib in untreated extensive-stage small-cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network","volume":"2","author":"Spigel","year":"2007","journal-title":"J Thorac Oncol"},{"issue":"18S suppl","key":"10.4065\/83.3.355_bib114","article-title":"Phase II trial of imatinib maintenance therapy after irinotecan and cisplatin in patients with c-kit positive extensive-stage small cell lung cancer (ES SCLC) [abstract 17089]","volume":"24","author":"Schneider","year":"2006","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.4065\/83.3.355_bib115","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/(SICI)1097-4652(199911)181:2<251::AID-JCP7>3.0.CO;2-D","article-title":"Antisense oligonucleotides as therapeutic agents","volume":"181","author":"Galderisi","year":"1999","journal-title":"J Cell Physiol"},{"issue":"14","key":"10.4065\/83.3.355_bib116","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1093\/jnci\/89.14.1027","article-title":"Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence","volume":"89","author":"Ziegler","year":"1997","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"10.4065\/83.3.355_bib117","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1038\/bjc.1998.624","article-title":"Synergistic cytotoxicity of bcl-2 antisense oligodeoxynucleotides and etoposide, doxorubicin and cisplatin on small-cell lung cancer cell lines","volume":"78","author":"Zangemeister-Wittke","year":"1998","journal-title":"Br J Cancer"},{"issue":"7042","key":"10.4065\/83.3.355_bib118","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nature03579","article-title":"An inhibitor of Bcl-2 family proteins induces regression of solid tumours","volume":"435","author":"Oltersdorf","year":"2005","journal-title":"Nature"},{"issue":"9","key":"10.4065\/83.3.355_bib119","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1097\/01243894-200611000-00013","article-title":"Bortezomib (PS-341) in relapsed or refractory extensive stage small cell lung cancer: a Southwest Oncology Group phase II trial (S0327)","volume":"1","author":"Lara","year":"2006","journal-title":"J Thorac Oncol"},{"issue":"18","key":"10.4065\/83.3.355_bib120","doi-asserted-by":"crossref","first-page":"8423","DOI":"10.1158\/0008-5472.CAN-05-0058","article-title":"Inhibition of the phosphatidylinositol 3-kinase\/Akt\/mammalian target of rapamycin pathway but not the MEK\/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy","volume":"65","author":"Tsurutani","year":"2005","journal-title":"Cancer Res"},{"issue":"4","key":"10.4065\/83.3.355_bib121","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1158\/1078-0432.CCR-04-1544","article-title":"The insulin-like growth factor-I receptor kinase inhibitor, NVP-ADW742, sensitizes small cell lung cancer cell lines to the effects of chemotherapy","volume":"11","author":"Warshamana-Greene","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.4065\/83.3.355_bib122","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1097\/JTO.0b013e318155a439","article-title":"A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: a trial of the Eastern Cooperative Oncology Group (E1500)","volume":"2","author":"Pandya","year":"2007","journal-title":"J Thorac Oncol"},{"issue":"22","key":"10.4065\/83.3.355_bib123","doi-asserted-by":"crossref","first-page":"4434","DOI":"10.1200\/JCO.2002.02.108","volume":"20","author":"Shepherd","year":"2002","journal-title":"J Clin Oncol"},{"issue":"18S suppl","key":"10.4065\/83.3.355_bib124","article-title":"A phase II study of cisplatin (P) plus etoposide (E) plus bevacizumab (B) for previously untreated extensive stage small cell lung cancer (SCLC) (E3501): a trial of the Eastern Cooperative Oncology Group [abstract 7564]","volume":"25","author":"Sandler","year":"2007","journal-title":"J Clin Oncol"},{"issue":"18S suppl","key":"10.4065\/83.3.355_bib125","article-title":"CALGB 30306: a phase II study of cisplatin (C), irinotecan (I) and bevacizumab (B) for untreated extensive stage small cell lung cancer (ES-SCLC) [abstract 7563]","volume":"25","author":"Ready","year":"2007","journal-title":"J Clin Oncol"},{"issue":"27","key":"10.4065\/83.3.355_bib126","doi-asserted-by":"crossref","first-page":"4278","DOI":"10.1200\/JCO.2007.12.3083","article-title":"Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20","volume":"25","author":"Arnold","year":"2007","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.4065\/83.3.355_bib127","doi-asserted-by":"crossref","first-page":"4082","DOI":"10.1073\/pnas.91.9.4082","article-title":"Thalidomide is an inhibitor of angiogenesis","volume":"91","author":"D'Amato","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"25","key":"10.4065\/83.3.355_bib128","doi-asserted-by":"crossref","first-page":"3945","DOI":"10.1200\/JCO.2007.11.8109","article-title":"Phase III double-blind, placebo-controlled study of thalidomide in extensive-disease small-cell lung cancer after response to chemotherapy: an intergroup study FNCLCC cleo04 IFCT 00-01","volume":"25","author":"Pujol","year":"2007","journal-title":"J Clin Oncol"},{"issue":"8 suppl 4","key":"10.4065\/83.3.355_bib129","doi-asserted-by":"crossref","first-page":"S306","DOI":"10.1097\/01.JTO.0000283089.56099.79","article-title":"A phase III randomised, double blind, placebo controlled trial of etoposide\/carboplatin with or without thalidomide in advanced small cell lung cancer (SCLC) [abstract PRS-04]","volume":"2","author":"Lee","year":"2007","journal-title":"J Thorac Oncol"},{"issue":"28","key":"10.4065\/83.3.355_bib130","doi-asserted-by":"crossref","first-page":"6854","DOI":"10.1200\/JCO.2005.17.186","article-title":"Phase III study of adjuvant vaccination with Bec2\/bacille Calmette-Guerin in responding patients with limited disease small cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; SILVA study)","volume":"23","author":"Giaccone","year":"2005","journal-title":"J Clin Oncol"},{"issue":"16S suppl","key":"10.4065\/83.3.355_bib131","article-title":"Phase II trial of BB-10901 (huN901-DM1) given weekly for four consecutive weeks every 6 weeks in patients with relapsed SCLC and CD56-positive small cell carcinoma [abstract 7159]","volume":"23","author":"Fossella","year":"2005","journal-title":"J Clin Oncol"},{"issue":"18S suppl","key":"10.4065\/83.3.355_bib132","article-title":"Phase II trial of huN901-DM1 in patients with relapsed small cell lung cancer (SCLC) and CD56-positive small cell carcinoma [abstract 18084]","volume":"25","author":"McCann","year":"2007","journal-title":"J Clin Oncol"},{"issue":"3, pt 1","key":"10.4065\/83.3.355_bib133","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1158\/1078-0432.CCR-05-2013","article-title":"Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer","volume":"12","author":"Antonia","year":"2006","journal-title":"Clin Cancer Res"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619611608719?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619611608719?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T01:23:16Z","timestamp":1589505796000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619611608719"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3]]},"references-count":133,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,3]]}},"alternative-id":["S0025619611608719"],"URL":"https:\/\/doi.org\/10.4065\/83.3.355","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2008,3]]}}}